Dollars for Profs

Dig Into University Researchers' Outside Income and Conflicts of Interest

Published Dec. 6, 2019

This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.

Financial doc
Filing Type

Conflict of Interest

Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.

Should you be removed from our database? Contact us at [email protected]. Read more below.

Brian Kaspar

Research Inst Nationwide Children's Hosp, Department: Na

Should you be removed from our database? Contact us at [email protected]. Read more below.

Disclosed Conflict of Interest with

AveXis

Disclosed Value
Listed Reason
Payment for services (e.g., consulting fees, honoraria, paid authorship)

Dr. Kaspar's invention (rights owned by Nationwide Children's Hospital) is licensed to AveXis. Dr. Kaspar's invention is the subject matter being tested under the Project funded by the U01 grant. Dr. Kaspar's financial ties to AveXis creates a potential conflict due to AveXis' potential financial gain from the research outcomes. The stock value may increase partially due to the outcome of this study. His fiduciary relationship as a board member inherently creates a conflict.

Listed Research Project
Translating a CSF delivered AAV9-SMN for treatment of Spinal Muscular Atrophy

We have discovered that systemically delivered AAV9-SMN delivered early to a severe rodent model of SMA results in substantial rescue of the lifespan. This work was published in Nature Biotechnology in 2010 as well as similar reports. We have expanded this work in additional studies with now over 50 animals that have been treated with scAAV9-SMN and had remarkably consistent results with long survival of SMA mice. In the initial phases of treatment the evaluator is completely blinded. However, while blinding is maintained throughout the study, it is obviously difficult to maintain a true blind status with suc a dramatic effect on survival. This sets the stage to advance to human clinical trials. However, systemic gene delivery, while it has certain advantages for the youngest patients, has limitations when advancing to the large and older patients. First, systemic gene delivery requires significant amounts of virus, and may be technically and economically challenging. Second, systemic gene delivery targets all organs, which may increase safety considerations, and in patients with neutralizing antibodies against AAV9 be less effective. We have recently discovered that AAV9, when delivered to the CSF results in efficient motor neuron targeting with a fraction of the virus utilized in our systemic gene delivery studies. When virus is delivered to the CSF, via intraventricular injections, we and others have demonstrated that SMA mice survive significantly longer, greater than 100 days of age, which is again a remarkable finding in a mouse model that typically dies at 15 days of age. This formulates the basis for the proposed U01 Application to advance to IND submission and human clinical trials.

Filed on August 26, 2014.

Tell us what you know about Brian Kaspar's disclosure

We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?

Name Institution Type Company Disclosed Value
Brian Kaspar Research Inst Nationwide Children's Hosp Conflict of Interest AveXis $0 - $4,999
Brian Kaspar Research Inst Nationwide Children's Hosp Conflict of Interest AveXis Value cannot be readily determined
If you see an error in the database or a reason we should not disclose a record, please contact us at [email protected] and we'll evaluate it on a case-by-case basis.
Sources: National Institutes of Health, public records requests filed at multiple public state universities

Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.

Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.

ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.

Close Comment Creative Commons Donate Email Facebook Mobile Phone Podcast Print RSS Search Search Twitter WhatsApp
Current site Current page